PXN and heart failure: Whereas 76.1% ± 15.4% of MO2-paxillin injected embryos developed contractile dysfunction, only 21.1% ± 10.95% of the embryos injected with MO2-paxillin and paxillin mRNA exhibited reduced cardiac contractility and heart failure (Fig 1J).